David Amsellem: Thanks. So, on Qelbree, can you talk about, Jack, where you see the mix between adults and pediatric evolving overtime? And I may have missed on your prepared remarks what you said on the current mix between adults impedes. But just talk about where you think that mix is going to go over time. Secondly, can you provide point more specifics on where you need to improve upon in terms of managed care access? And then third, just real quick on Oxtellar XR, I believe you have a generic filing — a trial on a generic filing pending. So just wanted to get your thoughts on that and the relative risk of potentially an earlier-than-expected loss of exclusivity Oxtellar. Thank you.
Jack Khattar : Sure. On the first question for Calgary in the mix of the business. I mean, where we are right now, we are about somewhere between 28%, 30% adult and the rest being pediatric. The market itself, if you remember, it’s basically almost the other way around, where the bulk of it is adult around 67%, and pediatric around 33%. So clearly as time goes on, we continue to expect to grow our business in the adult market. And will it eventually mimic exactly the market? We don’t know for sure. Obviously, we’re still early in the adult launch. Certainly, we’ve done extremely well and we’re very happy with the adult launch. And also, right now looking at the mix right now versus looking at it in the fall with the back-to-school season, but the mix may flip a little bit because you have a little bit more momentum behind the pediatric business in the back-to-school season.
So, these ratios are going to shift over time and continue to shift, but at some point, we will find ourselves probably closer to the market, but may not mimic it exactly. Regarding the next question on the managed care improvement, I mean, that is always an ongoing process. I mean, we will continue our discussions with other PBMs and continue to add contracts where it makes sense and where it is reasonable for us to enter these contracts. Same thing with the Medicaid and the different states. It’s an ongoing process where we always look for improving our position over time. And clearly, as time goes on, as utilization goes up, as we continue to be successful, as we’ve been in the last couple of years, improving the — and growing the prescriptions in a really solid way that even gives us further ammunition to go back and renegotiate contracts or try to improve our position as time goes on.
Regarding Oxtellar XR and the generic situation, we basically have three generic companies where we are — we have sued these three generic entrants that wanted to come in on Oxtellar XR. We are in the middle of litigations. I can’t really comment one way or the other, but there is certainly a risk on Oxtellar XR that we may be able to maintain exclusivity till the end of the patent expiration, which is 2027, or we may not. So, we really don’t know. We will certainly update the street on how things progress or don’t progress or whether any settlements occur if they do occur. So certainly, at this moment there is nothing really, I can report, but we will definitely report or announce anything if anything comes up. But certainly, there is a risk for us on Oxtellar XR as time goes on.
And I don’t know if I missed — was there a question on Trokendi XR?
David Amsellem: No, that’s it. Just on Oxtellar. I may have just follow up real quick. I mean, I believe you had prior litigation that you did win if I’m not mistaken. Is that, I just a quick refresher on that.
